ClinicalTrials.gg
Not yet recruitingNCT07157384REMIT2D isCGMUpdated Sep 5, 2025

REMIssion of Type 2 Diabetes Between Intermittently Scanned Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring When Added to Low-calorie Meal Replacement and Diabetes Self-management Education

An interventional study of Low calorie meal replacement plan and Diabetes self management education in Type 2 Diabetes, sponsored by LMC Diabetes & Endocrinology Ltd.. Not yet recruiting at 6 sites in Canada. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by LMC Diabetes & Endocrinology Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · LMC Diabetes & Endocrinology Ltd..

Started
2025
with 2 others
No phase
4 of 14
2 open now
Registered
12th of 14
by date

Among the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd., this one is one of 3 that started in 2025, is one of 4 with no phase, and was the 12th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd., or all of them as a file.
02

Study summary

The goal of the study is to evaluate the effectiveness of intermittently scanned continuous glucose monitoring compared to capillary blood glucose monitoring among people with type 2 diabetes initiating low calorie meal replacement plus diabetes self-management education in improving the proportion of patients achieving remission of type 2 diabetes. This is an open-label randomized controlled trial with 2 treatment arms randomized in a 1:1 manner.

The Investigators hypothesize that the use of intermittently scanned continuous glucose monitoring will improve the percentage of participants achieving remission of type 2 diabetes (remission to prediabetes or remission to normoglycemia), among adults with type 2 diabetes starting low calorie meal replacement and diabetes self-management education compared to a control group using capillary blood glucose monitoring at 18-30 weeks follow-up (end of Phase 2).

The primary outcome of the study is to compare the percentage of participants who achieve remission of type 2 diabetes (remission to prediabetes with HbA1c 6.0% to 6.4% or remission to normoglycemia with HbA1c \< 6.0% using no antihyperglycemic agents for ≥ 3 consecutive months) at 18-30 weeks follow-up between intermittently scanned continuous glucose monitoring vs. capillary blood glucose monitoring, when combined with low calorie meal replacement and diabetes self-management education.

Participants in both arms complete 3 phases of the study. Phase 1: total dietary replacement, Phase 2: food re-introduction and Phase 3: remission, while receiving diabetes self-management education sessions over a span of 18 months.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • low-calorie meal replacement
  • remission
  • intermittently scanned continuous glucose monitoring
  • type 2 diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years old
  • T2D treated with ≤ 3 non-insulin antihyperglycemic agents
  • A clinical diagnosis of T2D for > 6 months and ≤ 6 years ago
  • 6.0-9.0% on 2 or 3 antihyperglycemic agents, HbA1c 6.5-9.0% on 1 antihyperglycemic agent, or HbA1c 7.0-9.0% on 0 antihyperglycemic agents
  • 27-44.9 kg/m2
  • Not currently using a real-time CGM or isCGM
  • Willing to adhere to LCMR and initiate isCGM or CBG monitoring, and capable to do so as judged by investigator

Exclusion criteria

Exclusion Criteria:

  • Current or prior use of insulin (except for prior management of gestational diabetes mellitus)
  • Are pregnant or breastfeeding, or planning to become pregnant in the next 2 years
  • Severe or progressive retinopathy
  • Have a history of cardiovascular disease: coronary artery disease (CAD): prior myocardial infarction, previous unstable angina, documented CAD on angiography with stenosis >50%, imaging evidence of myocardial ischemia, coronary revascularization), peripheral arterial disease (lower extremity stenosis exceeding 50%, previous limb angioplasty, stenting or bypass surgery; or previous limb or foot amputation due to circulatory insufficiency or ankle brachial index of \< 0.9 in at least one limb.), cerebrovascular disease (history of ischemic or hemorrhagic stroke or > 50% carotid stenosis), or heart failure
  • Chronic kidney disease with estimated (eGFR) \< 60 ml/min/1.73 m2 or eGFR 60-90 ml/min/1.73 m2 with urine albumin to creatinine ratio (uACR) > 20 mg/mmol (any previously resolved macroalbuminuria will be considered as a reason for ineligibility, at the investigator's discretion)
  • Active binge eating disorder or other eating disorder
  • Uncontrolled mental health disorder
  • Current use of atypical antipsychotic or
  • Use of other implanted medical devices, such as pacemakers
  • Participant whose circumstance is deemed by investigator to be unadvisable, unsafe, or unlikely to be capable of adhering to LCMR and/or isCGM/CBG monitoring during the study period
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    isCGM + LCMR + DSME

    Group using an intermittently scanned continuous glucose monitor and receiving low calorie meal replacement and diabetes self management education

    Dietary Supplement: Low calorie meal replacement plan · Behavioral: Diabetes self management education · Device: Intermittently scanned continuous glucose monitoring

  • Active comparator
    CBG + LCMR + DSME

    Group using a capillary blood glucose monitor and receiving low calorie meal replacement and diabetes self management education

    Dietary Supplement: Low calorie meal replacement plan · Behavioral: Diabetes self management education · Device: capillary blood glucose monitoring

Interventions

  • Dietary supplementLow calorie meal replacement plan

    intervention provided to both arms in 2 out of the 3 study phases: Phase 1 (total dietary replacement) and Phase 2 (food re-introduction)

  • BehavioralDiabetes self management education

    intervention provided to both arms throughout study conducted as in-person session and telephone sessions

  • DeviceIntermittently scanned continuous glucose monitoring

    intervention provided to the intervention arm only: isCGM + LCMR + DSME

  • Devicecapillary blood glucose monitoring

    intervention provided to the control arm only: CBG + LCMR + DSME

06

What researchers measure

Primary outcomes

  1. Percentage of participants who achieve remission at the end of phase 2

    The primary objective is to compare the percentage of participants who achieve remission of T2D (remission to prediabetes with HbA1c 6.0% to 6.4% or remission to normoglycemia with HbA1c \< 6.0%) using no antihyperglycemic agents for ≥ 3 consecutive months at 18-30 weeks follow-up between isCGM vs. CBG monitoring, when combined with LCMR and DSME

    Time frame: from enrollment to end of phase 2 (18-30 weeks)

Secondary outcomes

  1. Proportion of participants achieving remission at the end of phase 1

    Evaluating the proportion of participants achieving remission of T2D (remission to prediabetes with HbA1c 6.0% to 6.4% or remission to normoglycemia with HbA1c \< 6.0%) using no antihyperglycemic agents for ≥ 3 consecutive months at 12-24 weeks follow-up between intervention and control (isCGM vs. CBG monitoring, when combined with LCMR and DSME)

    Time frame: from enrollment to end of phase 1 (12-24 weeks)

  2. Proportion of participants achieving remission to prediabetes at the end of phase 1

    Evaluating the proportion of participants between intervention and control groups achieving remission to prediabetes (HbA1c 6.0% to 6.4%) using no antihyperglycemic agents for ≥ 3 consecutive months at weeks 12-24 weeks follow-up

    Time frame: from enrollment to end of phase 1 (12-24 weeks)

  3. Proportion of participants achieving remission to normoglycemia at the end of phase 1

    Evaluating the proportion of participants between the intervention and control group achieving remission to normoglycemia (HbA1c \< 6.0%) using no antihyperglycemic agents for ≥ 3 consecutive months at weeks 12-24 weeks follow-up

    Time frame: from enrollment to end of phase 1 (12-24 weeks)

  4. Follow-up and change in HbA1c for the participants who did not initiate/reinitiate antihyperglycemic agents at the end of Phase 1

    comparing between intervention and control (isCGM vs. CBG monitoring, when combined with LCMR and DSME) the follow-up HbA1c (%) and the change in HbA1c (%) at the end of Phase 1 (12-24 weeks) for participants who did not initiate/reinitiate antihyperglycemic agents

    Time frame: from enrollment to end of Phase 1 (12-24 weeks)

  5. Adherence to low calorie meal replacement at the end of phase 1

    Comparing the adherence to low calorie meal replacement (LCMR), defined as a score of 3, 4 or 5 out of 5 for LCMR adherence measured using the adherence questionnaire between the intervention and the control group at the end of phase 1 (12-24 weeks). A higher score on the scale indicates better adherence.

    Time frame: from enrollment to end of Phase 1 (12-24 weeks)

  6. Percentage relapse at the end of Phase 1

    comparing the number of participants between intervention and control group that relapse during Phase 1, reported as a percentage. Relapse is defined as weight gain \> 2 kg from baseline body weight, HbA1c \> 9%, fasting glucose \> 11 mmol/L (on consecutive days, after first 4 weeks of LCMR), completely abandoning LCMR, and/or if participant needs to restart medications to lower their blood sugar (based on the doctor's recommendations).

    Time frame: from enrollment to end of Phase 1 (12-24 weeks)

  7. Time spent in Phase 1

    Comparing the time spent in Phase 1 (12-24 weeks) between intervention and control group. Time spent will be measured in weeks

    Time frame: from enrollment to end of phase 1 (12-24 weeks)

  8. Proportion of participants achieving remission to prediabetes at the end of phase 2

    Evaluating the proportion of participants between intervention and control groups achieving remission to prediabetes (HbA1c 6.0% to 6.4%) using no antihyperglycemic agents for ≥ 3 consecutive months at 18-30 weeks follow-up

    Time frame: from enrollment to end of phase 2 (18-30 weeks)

  9. Proportion of participants achieving remission to normoglycemia at the end of phase 2

    Evaluating the proportion of participants between the intervention and control group achieving remission to normoglycemia (HbA1c \< 6.0%) using no antihyperglycemic agents for ≥ 3 consecutive months at weeks 18-30 weeks follow-up

    Time frame: from enrollment to end of phase 2 (18-30 weeks)

  10. Follow-up and change of scores for Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) scale at the end of phase 2

    Evaluating the follow-up and change in scores for the Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) scale between the intervention and control group at the end of phase 2 ( 18-30 weeks). The DTSQs scale has 8 questions measured on a Likert scale from 6 (very satisfied) to 0 (very dissatisfied) about the participants satisfaction with their diabetes treatment in the last few weeks.

    Time frame: from enrollment to end of phase 2 (18-30 weeks)

  11. Follow-up and change in scores for the Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) scale at the end of phase 2

    Evaluating the follow-up and change in scores for the Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) scale between the intervention and control group at the end of phase 2 (18-30 weeks). The DTSQc scale has 8 questions measured on a Likert scale from 3 (much more satisfied now) to -3 (much less satisfied now) about the participants satisfaction of their diabetes treatment in the past 4-7 months.

    Time frame: from enrollment to end of phase 2 (18-30 weeks)

  12. Follow-up and change of scores in the Diabetes Distress scale (DDS) at the end of phase 2

    Evaluating the follow-up and change in scores in the Diabetes Distress scale (DDS) at the end of phase 2 (18-30 weeks) between intervention and control group. The DSS includes 17 questions measured on a Likert scale from 1 (not a problem) to 6 (a very serious problem) about the degree that diabetes has caused the participant distress in the past month. A higher score is reflective of more distress.

    Time frame: from enrollment to end of phase 2 (18-30 weeks)

  13. Proportion of participants achieving remission of T2D at the end of phase 3

    Evaluating the proportion of participants who achieve remission of T2D (remission to prediabetes with HbA1c 6.0% to 6.4% or remission to normoglycemia with HbA1c \< 6.0% using no antihyperglycemic agents for ≥ 3 consecutive months) at 30-44 weeks follow-up between intervention and control ( isCGM vs. CBG monitoring, when combined with LCMR and DSME)

    Time frame: from enrollment to end of phase 3 (30-44 weeks)

  14. Proportion of participants achieving remission to prediabetes at the end of phase 3

    Evaluating the proportion of participants achieving remission to prediabetes (HbA1c 6.0% to 6.4% using no antihyperglycemic agents for ≥ 3 consecutive months) at 30-44 weeks between intervention and control group (isCGM vs. CBG monitoring, when combined with LCMR and DSME)

    Time frame: from enrollment to end of phase 3 (30-44 weeks)

  15. Proportion of participants achieving remission to normoglycemia at the end of phase 3

    Evaluating the proportion of participants achieving remission to normoglycemia (HbA1c \< 6.0% using no antihyperglycemic agents for ≥ 3 consecutive months) at 30-44 weeks follow-up between intervention and control group ( isCGM vs. CBG monitoring, when combined with LCMR and DSME)

    Time frame: from enrollment to end of phase 3 (30-44 weeks)

  16. Evaluating the change in HbA1c at the end of phase 3

    Evaluating the change in HbA1c (%) at 30-44 weeks follow-up between intervention and control group

    Time frame: from enrollment to end of phase 3 (30-42 weeks)

  17. Low Calorie Meal Replacement persistence at the end of Phase 3

    Comparing the persistence to Low Calorie Meal Replacement (LCMR) in percentage between the intervention and the control group at the end of phase 3 (30-44 weeks).

    Time frame: End of Phase 3 (30-42 weeks)

  18. Proportion of participants initiating/reinitiating antihyperglycemic agents at the end of phase 3

    Evaluating the proportion of participants initiating/reinitiating antihyperglycemic agents at the end of phase 3 (30-44 weeks) between the intervention and control group.

    Time frame: from enrollment to end of phase 3 ( 30-44 weeks)

  19. Follow-up and change in body weight at the end of phase 3

    Evaluating the follow-up and change in body weight (kg) at the end of phase 3 (30-44 weeks) between the intervention and control group

    Time frame: from enrollment to end of phase 3 (30-44 weeks)

  20. Follow-up and change in BMI at the end of phase 3

    Evaluating the follow-up and change in BMI (kg/m\^2) at the end of phase 3 ( 30-44 weeks) between the intervention and control group

    Time frame: from enrollment to end of Phase 3 (30-44 weeks)

  21. Percent weight loss at the end of Phase 3

    Evaluating the percent weight loss at the end of Phase 3 (30-44 weeks) between the intervention and control group

    Time frame: from enrollment to end of Phase 3 (30-44 weeks)

  22. Follow-up and change in scores for the Diabetes Treatment Satisfaction Questionnaire status version at the end of Phase 3

    Evaluating the follow-up and change in scores for the Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) between the intervention and control group at the end of phase 3 (30-44 weeks). The DTSQs scale has 8 questions measured on a Likert scale from 6 (very satisfied) to 0 (very dissatisfied) about the participants satisfaction with their diabetes treatment in the last few weeks.

    Time frame: from enrollment to end of Phase 3 ( 30-44 weeks)

  23. Follow-up and change in scores in the Diabetes Distress scale (DDS) at the end of phase 3

    Evaluating the follow-up and change in scores in the Diabetes Distress scale (DDS) at the end of phase 3 (30-44 weeks) between intervention and control group. The DSS includes 17 questions measured on a Likert scale from 1 (not a problem) to 6 (a very serious problem) about the degree that diabetes has caused the participant distress in the past month. A higher score is reflective of more distress

    Time frame: from enrollment to end of Phase 3 (30-44 weeks)

  24. Change in Percent Time in Range (TIR) at the end of Phase 3

    Evaluating the change in percent TIR (3.9 to 10.0 mmol/L) at the end of phase 3 (30-44 weeks) from baseline between intervention and control group

    Time frame: from enrollment to end of Phase 3 (30-44 weeks)

  25. Change in Percent Tight Time in Range (TITR) at the end of Phase 3

    Evaluating the change in percent TITR (3.9 to 7.8 mmol/L) at the end of phase 3 (30-44 weeks) from baseline between intervention and control group

    Time frame: enrollment to end of Phase 3 (30-44 weeks)

  26. Change in Percent Time Below Range (TBR) at the end of Phase 3

    Evaluating the change in percent TBR (≤ 3.8 mmol/L) at the end of phase 3 (30-44 weeks) from baseline between intervention and control group

    Time frame: from enrollment to end of phase 3 (30-44 weeks)

  27. Change in Percent Time Below Range Level 1 at the end of Phase 3

    Evaluating the change in percent TBR level 1 hypoglycemia range (3.0 to 3.8 mmol/L) at the end of phase 3 (30-44 weeks) from baseline between intervention and control group

    Time frame: from enrollment to end of Phase 3 (30-44 weeks)

  28. Change in Percent Time Below Range Level 2 at the end of Phase 3

    Evaluating the change in percent TBR level 2 hypoglycemia range (\< 3.0 mmol/L)at the end of phase 3 (30-44 weeks) from baseline between intervention and control group

    Time frame: from enrollment to end of Phase 3 (30-44 weeks)

  29. Change in Percent Time Above Range (TAR) at the end of Phase 3

    Evaluating the change in percent TAR (\> 10.0 mmol/L) at the end of phase 3 (30-44 weeks) from baseline between intervention and control group

    Time frame: from enrollment to end of Phase 3

  30. Change in mean glucose at the end of Phase 3

    Evaluating the change in mean glucose (mmol/L) at the end of phase 3 (30-44 weeks) from baseline between the intervention and control group.

    Time frame: from enrollment to end of Phase 3 (30-44 weeks)

  31. Change in Glycemic Variability at the end of Phase 3

    Evaluating change in glycemic variability (standard deviation and % coefficient of variation) from baseline to the end of Phase 3 (30-44 weeks) between the intervention and control group.

    Time frame: from enrollment to end of Phase 3 (30-44 weeks)

  32. Change in Glucose Management Indicator at the end of Phase 3

    Evaluating the change in Glucose management indicator, measured in percentage (%) between the intervention and control group from baseline to the end of Phase 3 (30-44 weeks)

    Time frame: from enrollment to end of Phase 3 (30-44 weeks)

Other outcomes

  1. Evaluating isCGM metrics at the end of phase 3 between isCGM+ LCMR+ DSME and CBG+ LMCR+ DSME

    Evaluating isCGM metrics (collected from a blinded isCGM) between isCGM vs. CBG monitoring, when combined with LCMR and DSME at 30-42 weeks follow-up. We will describe the mean (SD) and/or median (IQR) for TIR and TITR among the pooled sample of participants from both randomized arms (isCGM and CBG) achieving remission to prediabetes or remission to normoglycemia.

    Time frame: End of Phase 3 (30-44 weeks)

07

Study locations

6 sites
  • LMC Brampton
    Brampton, Ontario, Canada
    • Manager, Data Science · Contactlisa.chu@lmc.ca
    • Research Assistant, Data Science · Contactgiovana.romero@lmc.ca
    • Nadeem Aslam, MD · Sub investigator
    • Harpreet Bajaj, MD · Principal investigator
  • LMC Etobicoke
    Etobicoke, Ontario, Canada
  • LMC Oakville
    Oakville, Ontario, Canada
    • Manager, Data Science · Contactlisa.chu@lmc.ca
    • Research Assistant, Data Science · Contactgiovana.romero@lmc.ca
    • Alexander Abitbol, MD · Sub investigator
    • David Twum-Barima, MD · Sub investigator
  • LMC Ottawa
    Ottawa, Ontario, Canada
  • LMC Bayview
    Toronto, Ontario M4G 3E8, Canada
    • Manager, Data Science · Contactlisa.chu@lmc.ca · 14166452929
    • Research Assistant, Data Science · Contactgiovana.romero@lmc.ca
    • Alexander Abitbol, MD · Principal investigator
    • Ronnie Aronson, MD · Sub investigator
  • LMC Vaughan
    Vaughan, Ontario, Canada
    • Manager, Data Science · Contactlisa.chu@lmc.ca
    • Research Assistant, Data Science · Contactgiovana.romero@lmc.ca
    • David Sionit, MD · Sub investigator
    • Chris D'Sylva, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Mar 2027, 18 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 18 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Sep 5, 2025
StartEst.
Sep 2025
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07157384
Lead sponsor
LMC Diabetes & Endocrinology Ltd.
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Sep 2025 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 5, 2025

Study contacts

Manager, Data Science
Contact
lisa.chu@lmc.ca
14166452929
Research Assistant, Data Science
Contact
giovana.romero@lmc.ca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion